Henry Schein (HSIC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, to be held virtually, with voting on directors, executive compensation, auditor ratification, and a shareholder proposal on majority voting.
Frederick M. Lowery appointed CEO effective March 2, 2026, succeeding Stanley M. Bergman, who retired as CEO but remains Chairman until the end of the Annual Meeting.
Board size reduced from fifteen to ten members, with four directors not standing for reelection.
KKR increased its ownership limit to 19.9% and maintains two board designees.
Voting matters and shareholder proposals
Proposals include election of ten incumbent directors, advisory vote on executive compensation (say-on-pay), ratification of BDO USA as auditor, and a shareholder proposal to eliminate supermajority voting requirements.
Board recommends voting for all directors, for say-on-pay and auditor ratification, and against the majority vote shareholder proposal.
Shareholder proposal seeks to replace all supermajority voting standards with simple majority; Board opposes, citing limited use and benefits of current provisions.
Board of directors and corporate governance
Board composition now includes nine independent directors and one executive (CEO), with average tenure of 6.2 years.
Board committees: Audit, Compensation, Nominating and Governance, Regulatory/Compliance/Cybersecurity, and Strategic Advisory.
Annual board and committee self-assessments, director time commitment and retirement policies, and robust stock ownership guidelines in place.
Lead Director role continues to support independent oversight.
Latest events from Henry Schein
- Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 202613 May 2026 - Board urges support for director nominees and opposes majority vote proposal at annual meeting.HSIC
Proxy filing12 May 2026 - Q1 2026 delivered strong sales, margin, and EPS growth, with guidance and value initiatives reaffirmed.HSIC
Q1 20265 May 2026 - $13.2B FY2025 sales, digital transformation, and high-margin growth drive long-term value.HSIC
Corporate presentation5 May 2026 - Key votes include director elections, executive pay, auditor ratification, and majority voting.HSIC
Proxy filing8 Apr 2026 - $13.2B in 2025 sales with strong specialty, technology, and high-margin business growth.HSIC
Corporate presentation13 Mar 2026 - Dental segment growth, digital innovation, and leadership changes drive optimism for 2026.HSIC
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Operational shift, AI innovation, and specialty growth drive margin and market share gains.HSIC
Leerink Global Healthcare Conference 20269 Mar 2026 - Record sales and earnings growth in Q4 2025, with a strong outlook for 2026.HSIC
Q4 202524 Feb 2026